Safety and Efficacy Study in Adult Subjects With Acute Migraines
Migraine, With or Without Aura
About this trial
This is an interventional treatment trial for Migraine, With or Without Aura
Eligibility Criteria
Key Inclusion Criteria:
Patient has at least 1 year history of migraines (with or without aura), consistent with a diagnosis according to the International Classification of Headache Disorder, 3rd Edition, Beta version[1] including the following:
- Not more than 8 attacks of moderate or severe intensity per month within last 3 months
- Consistent migraine headaches of at least 2 migraine headache attacks of moderate or severe intensity in each of the 3 months prior to the Screening Visit and maintains this requirement during the Screening Period
- Less than 15 days with headache (migraine or non-migraine) per month in each of the 3 months prior to the Screening Visit and maintains this requirement during the Screening Period
- Patients on prophylactic migraine medication are permitted to remain on therapy provided they have been on a stable dose for at least 3 months prior to study entry.
- Patients with contraindications for use of triptans may be included provided they meet all other study entry criteria.
Key Exclusion Criteria:
- Patient history of HIV disease
- Patient history with current evidence of uncontrolled, unstable or recently diagnosed cardiovascular disease, such as ischemic heart disease, coronary artery vasospasm, and cerebral ischemia. Patients with Myocardial Infarction (MI), Acute Coronary Syndrome (ACS),Percutaneous Coronary Intervention (PCI), cardiac surgery, stroke or transient ischemic attack (TIA) during the 6 months prior to screening.
- Uncontrolled hypertension (high blood pressure), or uncontrolled diabetes (however patients can be included who have stable hypertension and/or diabetes for 3 months prior to being enrolled)
- Patient has a current diagnosis of major depression, other pain syndromes, psychiatric conditions (eg, schizophrenia), dementia, or significant neurological disorders (other than migraine) that, in the Investigator's opinion, might interfere with study assessments
- Patient has a history of gastric, or small intestinal surgery, or has a disease that causes mal-absorption
- The patient has a history or current evidence of any significant and/or unstable medical conditions (eg, history of congenital heart disease or arrhythmia, known suspected infection, hepatitis B or C, or cancer) that, in the investigator's opinion, would expose them to undue risk of a significant adverse event (AE) or interfere with assessments of safety or efficacy during the course of the trial
- History of, treatment for, or evidence of, alcohol or drug abuse within the past 12 months or patients who have met DSM-V criteria for any significant substance use disorder within the past 12 months from the date of the screening visit.
Sites / Locations
- Central Research Associates, Inc
- Neurological Physicians of Arizona/Radiant Research Inc
- Clinical Research Consortium Arizona
- Radiant Research, Inc.
- Woodland International Research Group, LLC
- Pharmacology Research Institute
- Optimus Medical Group
- California Medical Clinic for Headache
- Diablo Clinical Research, Inc
- Qps Mra, Llc
- Multi-Specialty Research Associates, Inc
- Qps Mra, Llc
- Advanced Pharma CR, LLC
- Compass Research, LLC
- Ormond Medical Arts Pharmaceutical Research
- Meridian Clinical Research
- New Orleans Center for Clinical Research
- Boston Clinical Trials, Inc
- Milford Emergency Associates, Inc.
- Michigan Head Pain & Neurological Institute
- Clinical Research Institute, Inc
- Clinical Research Institute
- The Center for Pharmaceutical Research
- Sundance Clinical Research, LLC
- Meridian Clinical Research -Norfolk
- Meridian Clinical Research, LLC
- Clinical Research Consortium- Las Vegas
- Hassman Research Institute, LLC
- SPRI Clinical Trials, LLC
- Regional Clinical Research, Inc.
- Central New York Clinical Research
- Fieve Clinical Research
- Rochester Clinical Research, Inc
- PharmQuest, LLC
- CTI Clinical Research Center
- Oregon Center for Clinical Investigations, Inc
- Clinical Research of Philadelphia, LLC
- Preferred Primary Care Physicians
- Omega Medical Research
- Coastal Carolina Research Center
- Meridian Clinical Research
- FutureSearch Trials of Neurology, LP
- FutureSearch Trials of Neurology, LP
- Texas Center for Drug Development
- J.Lewis Research Inc / Foothill Family Clinic South
- J.Lewis Research Inc. / Jordan River Family Med
- Clinical Research Associates of Tidewater, Inc.
- Tidewater Integrated Medical Research
- Northwest Clinical Research Center
- Seattle Women's:Health, Research & Gynecology
Arms of the Study
Arm 1
Arm 2
Experimental
Placebo Comparator
Rimegepant 75 mg
Placebo
Participants were administered a single oral dose of 75 mg of rimegepant tablet on occurrence of migraine that reached moderate or severe intensity up to 45 days after randomization.
Participants were administered a single oral dose of matching placebo tablet for rimegepant (75 mg) on occurrence of migraine that reached moderate or severe intensity up to 45 days after randomization.